BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 36198236)

  • 1. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability.
    Eptaminitaki GC; Stellas D; Bonavida B; Baritaki S
    Drug Resist Updat; 2022 Dec; 65():100866. PubMed ID: 36198236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory effects of lncRNAs and miRNAs on the crosstalk between autophagy and EMT in cancer: a new era for cancer treatment.
    Si L; Yang Z; Ding L; Zhang D
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):547-564. PubMed ID: 35083552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNAs: An emerging powerhouse in the battle between life and death of tumor cells.
    Xiong XD; Ren X; Cai MY; Yang JW; Liu X; Yang JM
    Drug Resist Updat; 2016 May; 26():28-42. PubMed ID: 27180308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting.
    Singh D; Khan MA; Siddique HR
    Mol Biol Rep; 2020 Jul; 47(7):5569-5585. PubMed ID: 32601922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of long non-coding RNAs in drug resistance of cancer.
    Zhang HD; Jiang LH; Zhong SL; Li J; Sun DW; Hou JC; Wang DD; Zhou SY; Tang JH
    Clin Genet; 2021 Jan; 99(1):84-92. PubMed ID: 32583420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of long non-coding RNAs in mediating chemoresistance by modulating autophagy in cancer.
    Jin KT; Lu ZB; Lv JQ; Zhang JG
    RNA Biol; 2020 Dec; 17(12):1727-1740. PubMed ID: 32129701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
    Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of noncoding RNAs in colorectal cancer chemoresistance.
    Wei L; Wang X; Lv L; Zheng Y; Zhang N; Yang M
    Cell Oncol (Dordr); 2019 Dec; 42(6):757-768. PubMed ID: 31359293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNAs in cancer drug resistance development.
    Majidinia M; Yousefi B
    DNA Repair (Amst); 2016 Sep; 45():25-33. PubMed ID: 27427176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNHG11: A New Budding Star in Tumors and Inflammatory Diseases.
    Wu Y
    Mini Rev Med Chem; 2023; 23(20):1993-2006. PubMed ID: 37165588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA as a multifunctional regulator in cancer multi-drug resistance.
    He J; Zhu S; Liang X; Zhang Q; Luo X; Liu C; Song L
    Mol Biol Rep; 2021 Aug; 48(8):1-15. PubMed ID: 34333735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lnc2Cancer 3.0: an updated resource for experimentally supported lncRNA/circRNA cancer associations and web tools based on RNA-seq and scRNA-seq data.
    Gao Y; Shang S; Guo S; Li X; Zhou H; Liu H; Sun Y; Wang J; Wang P; Zhi H; Li X; Ning S; Zhang Y
    Nucleic Acids Res; 2021 Jan; 49(D1):D1251-D1258. PubMed ID: 33219685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers.
    Kichi ZA; Soltani M; Rezaei M; Shirvani-Farsani Z; Rojhannezhad M
    Curr Med Chem; 2022; 29(26):4574-4601. PubMed ID: 35352644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNAs Roles in Chemoresistance of Cancer Cells.
    Taghvimi S; Abbaszadeh S; Banan FB; Fard ES; Jamali Z; Najafabadi MA; Savardashtaki A; Movahedpour A
    Curr Mol Med; 2022; 22(8):691-702. PubMed ID: 34711162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer.
    Peng Y; Tang D; Zhao M; Kajiyama H; Kikkawa F; Kondo Y
    Cancer Metastasis Rev; 2020 Sep; 39(3):825-835. PubMed ID: 32594276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions.
    Entezari M; Taheriazam A; Orouei S; Fallah S; Sanaei A; Hejazi ES; Kakavand A; Rezaei S; Heidari H; Behroozaghdam M; Daneshi S; Salimimoghadam S; Mirzaei S; Hashemi M; Samarghandian S
    Biomed Pharmacother; 2022 Oct; 154():113609. PubMed ID: 36037786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer.
    Zhang X; Yang H
    Clin Breast Cancer; 2020 Aug; 20(4):275-282. PubMed ID: 32414649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
    Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
    Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs.
    Jiang W; Xia J; Xie S; Zou R; Pan S; Wang ZW; Assaraf YG; Zhu X
    Drug Resist Updat; 2020 May; 50():100683. PubMed ID: 32146422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.
    Venkatesh J; Wasson MD; Brown JM; Fernando W; Marcato P
    Cancer Lett; 2021 Jul; 509():81-88. PubMed ID: 33848519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.